Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
Rusfertide met all primary and secondary endpoints in a Phase 3 trial for polycythemia vera, with strong efficacy and safety ...
Hosted on MSN1h
Takeda and Protagonist report topline outcomes from trial of rusfertide
Takeda and Protagonist Therapeutics have reported positive topline outcomes from their Phase III VERIFY trial of rusfertide ...
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., March 03, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX ...
Sun Journal1mon
Periodic phlebotomies required for hemochromatosis patient
I am a male and would like to know if I need to continue getting phlebotomies. After several phlebotomies in three to four months, my level was 122 ng/mL. Currently, I have a score of 97 ng/mL.
The Telegraph1mon
Periodic phlebotomies required for hemochromatosis patient
I am a male and would like to know if I need to continue getting phlebotomies. After several phlebotomies in three to four months, my level was 122 ng/mL. Currently, I have a score of 97 ng/mL. I ...
St. Louis Post-Dispatch1mon
Dr. Roach: Periodic phlebotomies required for hemochromatosis patient
I am a male and would like to know if I need to continue getting phlebotomies. After several phlebotomies in three to four months, my level was 122 ng/mL. Currently, I have a score of 97 ng/mL.